"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: A double-blind, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 72, Issue 8, 2011, Pages 1042-1048

  Remington, Gary ^a,b   Seeman, Philip ^b   Feingold, Alan ^c,d   Mann, Steve ^a   Shammi, Chekkera ^a,b   Kapur, Shitij ^b,e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OREGON SOCIAL LEARNING CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; BARNES AKATHISIA SCALE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITAL READMISSION; HUMAN; LONG TERM CARE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; SINGLE DRUG DOSE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRIEF PSYCHIATRIC RATING SCALE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LOXAPINE; MALE; MIDDLE AGED; ONTARIO; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 80052466025     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05866yel     Document Type: Article

References (50)

1. Almerie MQ, Alkhateeb H, Essali A, et al. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database Syst Rev. 2007;(1):CD006329. PubMed
2. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52(3):173-188. PubMed
3. Hogarty GE, Goldberg SC, Schooler NR. Drug and sociotherapy in the aftercare of schizophrenic patients, III: adjustment of nonrelapsed patients. Arch Gen Psychiatry. 1974;31(5):609-618. PubMed
4. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247. doi:10.101/archpsyc.56.3.241 PubMed
5. Lindenmayer JP, Khan A, Wance D, et al. Outcome evaluation of a structured educational wellness program in patients with severe mental illness. J Clin Psychiatry. 2009;70(10):1385-1396. doi:10.408/JCP.08m04740yel PubMed
6. Ereshefsky L, Saklad SR, Tran-Johnson T, et al. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Psychopharmacol Bull. 1990;26(1):108-114. PubMed
7. Nayak RK, Doose DR, Nair NP. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol. 1987;27(2):144-150. PubMed
8. Simpson GM, Yadalam KG, Levinson DF, et al. Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J Clin Psychopharmacol. 1990;10(6):417-421. doi:10.1097/04714-1901060-07 PubMed
9. Yasui-Furukori N, Kondo T, Mihara K, et al. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. J Clin Pharmacol. 2002;42(10):1083-1088. doi:10.17/0912702401382678 PubMed
10. Carpenter WT Jr. Early, targeted pharmacotherapeutic intervention in schizophrenia. J Clin Psychiatry. 1986;47(suppl):23-29. PubMed
11. Carpenter WT Jr, Heinrichs DW, Hanlon TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry. 1987;144(11):1466- 1470. PubMed
12. Carpenter WT Jr, Heinrichs DW. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull. 1983;9(4):533-542. PubMed
13. Chiles JA, Sterchi D, Hyde T, et al. Intermittent medication for schizophrenic outpatients: who is eligible? Schizophr Bull. 1989;15(1):117-121. PubMed
14. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry. 1990;147(9):1138-1148. PubMed
15. Gaebel W. Is intermittent, early intervention medication an alternative for neuroleptic maintenance treatment? Int Clin Psychopharmacol. 1995;9(suppl 5):11-16. doi:10.1097/04850-1950105-03 PubMed
16. Herz MI, Glazer W, Mirza M, et al. Intermittent medication in schizophrenia: a preliminary report. In: Schulz SC, Tamminga C, eds. Schizophrenia: Scientific Progress. New York, NY: Oxford; 1989:333-340.
17. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry. 1991;48(4):333-339. PubMed
18. Jolley AG, Hirsch SR, McRink A, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ. 1989;298(6679):985-990. doi:10.136/bmj.298.679.985 PubMed
19. Jolley AG, Hirsch SR, Morrison E, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ. 1990;301(6756):837-842. doi:10.136/bmj.301. 6756.837 PubMed
20. Pietzcker A, Gaebel W, Köpcke W, et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia: 2-year results of a German multicenter study. J Psychiatr Res. 1993;27(4):321-339. doi:10.1016/02-3956(93)9059-B
21. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50(11):873-883. doi:10.1016/S06-323(01)01251-3 PubMed
22. 2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry. 2001;158(3):360-369. doi:10.176/api.ajp.158.3.360 PubMed
23. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38. PubMed
24. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998;3(2):123-134. doi:10.1038/sj.mp.4036 PubMed
25. Samaha AN, Reckless GE, Seeman P, et al. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry. 2008;64(2):145-152. doi:10.1016/j.biopsych.208.01.010 PubMed
26. Samaha AN, Seeman P, Stewart J, et al. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27(11):2979-2986. doi:10.1523/JNEUROSCI. 5416-06.207 PubMed
27. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. doi:10.176/api.ajp.157.4.514 PubMed
28. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33(4):227-235. doi:10.1016/06-323(93)9028-O PubMed
29. 2 receptors from plasma levels. Psychopharmacology (Berl). 2000;149(1):1-5. doi:10.107/s0213903 PubMed
30. 2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry. 2008;69(8):1281-1286. doi:10.408/JCP.v69n081 PubMed
31. Remington G, Seeman P, Shammi C, et al. "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol. 2005;25(6):611-613. doi:10.1097/01.jcp.0185341.5096.65 PubMed
32. Boshes RA, Manschreck TC. Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr Bull. 2002;28(2):203-222. PubMed
33. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114(1):3-13. doi:10.1/j.160-047.206.0787.x PubMed
34. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry. 1999;156(6):876-884. PubMed
35. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10(3):799-812. doi:10.246/PR0.10.3.79-812
36. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976.
37. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3(4):247-251. doi:10.1016/0920-964(90)905-R PubMed
38. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. doi:10.192/bjp.154.5.672 PubMed
39. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;45(S212):11-19. doi:10.1/j.160-047.1970.tb0206. x PubMed
40. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;19(3):609-618. PubMed
41. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891. doi:10.176/api.ps.5.8.86 PubMed
42. Newton JE, Cannon DJ, Couch L, et al. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. J Clin Psychiatry. 1989;50(4):132-135. PubMed
43. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, et al. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry. 1999;156(3):412-418. PubMed
44. Rutten BP, Mill J. Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull. 2009;35(6):1045-1056. doi:10.1093/schbul/sbp104 PubMed
45. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008, 2. Epidemiology and etiology. Schizophr Res. 2008;102(1-3):1-18. doi:10.1016/j.schres.208.04.01 PubMed
46. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635-645. doi:10.1016/S0140-6736(09)6095-8 PubMed
47. Remington G, Kwon J, Collins A, et al. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res. 2007;90(1-3):229-237. doi:10.1016/j.schres.206.1.015 PubMed
48. Malek-Ahmadi P, Chapel JL. Tolerance to phenothiazines in schizophrenic patients. Gen Pharmacol. 1976;7(6):377-379. PubMed
49. Margolese HC, Chouinard G, Beauclair L, et al. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol. 2002;22(4):347-352. doi:10.1097/04714-202080-03 PubMed
50. Sramek JJ, Gaurano V, Herrera JM, et al. Patterns of neuroleptic usage in continuously hospitalized chronic schizophrenic patients: evidence for development of drug tolerance. DICP. 1990;24(1):7-10. PubMed